Loading
A phase 2 study of brentuximab vedotin in mycosis fungoides and Sézary syndrome, not Hodgkin lymphoma: 21 of 30 people responded, and those whose tumours had less than 5 per cent CD30 were less likely to.
Purpose: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable. Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored.
Patients and methods: In this phase II study, patients with MF or SS with negligible to 100% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses. The primary end point was overall global response rate. Secondary end points included correlation of tissue CD30 expression level with clinical response, time to response, duration of response, progression-free and event-free survivals, and safety.
Results: Of the 32 patients enrolled and treated, 30 patients had available efficacy evaluations. Objective global response was observed in 21 (70%) of 30 patients (90% CI, 53% to 83%). CD30 expression assessed by immunohistochemistry was highly variable, with a median CD30max of 13% (range, 0% to 100%). Those with <5% CD30 expression had a lower likelihood of global response than did those with 5% or greater CD30 expression (P <.005). CD163 positive tumor-associated macrophages, many of which coexpress CD30, were abundant in tissue. Peripheral neuropathy was the most common adverse event.
Conclusion: Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin.
Indexed on Europe PMC as PubMed record 26195720 (DOI 10.1200/jco.2014.60.3969). Its title names CD30 and its text names Hodgkin lymphoma; PubMed types it as a clinical trial report (Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, research-article, Multicenter Study). It was matched automatically to the idea "CD30 CAR-T for multiply relapsed Hodgkin lymphoma" and no figure has been checked by an editor.
Evidence that brentuximab vedotin works in mycosis fungoides and Sézary syndrome across a wide range of CD30 expression. It was matched automatically to a Hodgkin lymphoma idea because its abstract mentions Hodgkin lymphoma in passing; the study enrolled no one with Hodgkin lymphoma (corrected by hand on 3 November 2026; the generator carries existing records through unchanged). Read the abstract above and the paper itself before relying on any figure.
Shares CD30 CAR-T for multiply relapsed Hodgkin lymphoma, Journal of Clinical Oncology.
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/